Half Dose Once-Daily Pemafibrate Effectively Improved Hypertriglyceridemia in Real Practice
- PMID: 31636783
- PMCID: PMC6785276
- DOI: 10.14740/jocmr3949
Half Dose Once-Daily Pemafibrate Effectively Improved Hypertriglyceridemia in Real Practice
Abstract
Background: Hyperlipidemia is a worldwide problem related to cardiovascular disease (CVD) and sudden death. Low-density lipoprotein cholesterol (LDL-C) has been treated well by the use of statins, but hypertriglyceridemia was not the case. Previous fibrates have been shown a certain effect of preventing CVD events, but some remain not enough or even could cause adverse events. Pemafibrate is a selective peroxisome proliferator-activated receptor α modulator (SPPARMα) with the potential to reduce high triglycerides. To evaluate the clinical effectiveness and safety profile of Pemafibrate, we have started with half dose once-daily administration.
Methods: Thirty-three patients with hypertriglyceridemia, triglyceride (TG) levels > 150 mg/dL, were treated with Pemafibrate (0.1 mg, once daily) from July 2018 to February 2019. Changes in TG (non-fasting) and LDL-C, high-density lipoprotein cholesterol (HDL-C), aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine kinase (CK), creatinine (Cre), blood glucose (PBG) (postprandial), hemoglobin A1c (HbA1c), and body weight (BW) levels were investigated, compared to the baseline levels of the previous visit.
Results: Of the 33 patients, 11 were using other fibrates before. Nine were given statins along with. Baseline TG was 285.0 (210.5 - 423.0) mg/dL, LDL-C 116.4 ± 33.4 mg/dL, and HDL-C 46.5 ± 12.5 mg/dL. TG changes were statistically significant (-20.8 ± 47.6%; P < 0.01). Patients with TG > 200 mg/dL, who used fibrates for the first time, experienced the most significant changes in TG levels (-34.5 ± 37.2%; P < 0.01). In patients using statins already, TG reduction was relatively less, compared to those not using statins (-25.4 ± 36.1%; P < 0.01). HDL-C increased by 3.9 ± 10.2 mg/dL (P < 0.05). LDL-C increased by 16.6 ± 23.7 mg/dL (P < 0.001) in patients not using statins, while patients using statins did not show such significant change. AST, ALT, CK, Cre, PBG, HbA1c and BW did not significantly change.
Conclusions: A selective PPARα modulator, Pemafibrate, effectively improved hypertriglyceridemia without major adverse events in real practice, with half dose once-daily administration. Combined use of statins might be a potent therapeutic maneuver for dyslipidemia.
Keywords: Hypertriglyceridemia; Pemafibrate; SPPARMα; Statins.
Copyright 2019, Iitake et al.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Similar articles
-
Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.Cardiovasc Diabetol. 2020 Nov 27;19(1):201. doi: 10.1186/s12933-020-01172-8. Cardiovasc Diabetol. 2020. PMID: 33246467 Free PMC article.
-
Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis.Metabolites. 2023 May 2;13(5):626. doi: 10.3390/metabo13050626. Metabolites. 2023. PMID: 37233667 Free PMC article. Review.
-
Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.Diabetes Care. 2022 Apr 1;45(4):898-908. doi: 10.2337/dc21-1288. Diabetes Care. 2022. PMID: 35238894 Clinical Trial.
-
Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.Curr Atheroscler Rep. 2020 Jan 23;22(1):5. doi: 10.1007/s11883-020-0823-5. Curr Atheroscler Rep. 2020. PMID: 31974794 Free PMC article. Review.
-
Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases.J Atheroscler Thromb. 2019 May 1;26(5):389-402. doi: 10.5551/jat.48918. Epub 2019 Mar 30. J Atheroscler Thromb. 2019. PMID: 30930344 Free PMC article. Review.
Cited by
-
Clinical Efficacy and Safety of Low-Dose Pemafibrate in Patients With Severe Renal Impairment: A Retrospective Study.Cureus. 2024 Apr 7;16(4):e57777. doi: 10.7759/cureus.57777. eCollection 2024 Apr. Cureus. 2024. PMID: 38715994 Free PMC article.
-
Efficacy and Safety of Low-Dose Pemafibrate Therapy for Hypertriglyceridemia in Patients with Type 2 Diabetes.JMA J. 2021 Apr 15;4(2):135-140. doi: 10.31662/jmaj.2020-0104. Epub 2021 Mar 26. JMA J. 2021. PMID: 33997447 Free PMC article.
-
Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.Cardiovasc Diabetol. 2020 Nov 27;19(1):201. doi: 10.1186/s12933-020-01172-8. Cardiovasc Diabetol. 2020. PMID: 33246467 Free PMC article.
References
-
- Yamada N. Ministry of Health, Labor and Welfare Sciences Research Grant, Prospective study for improving the quality of life, vascular complication and long term prognosis of type 2 diabetic patients, Japan Diabetes Complication Study, Summary research report Fiscal Year 2007 (MHLW GRANTS SYSTEM). http://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=200722056A.
-
- Teramoto T, Sakuma T, Nakao K, Yamamoto O. ALWAYS study group. Atorvastatin Lipid lowering Assessment survey in patients with hypercholesterolemia(ALWAYS), Final Report: investigation according to Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. Ther Res. 2013;34(4):455–483.
-
- Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, Ginsberg H. et al. Rationale and design of the pemafibrate to reduce cardiovascular outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J. 2018;206:80–93. doi: 10.1016/j.ahj.2018.09.011. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous